Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 9/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.36 |
| ▸ | ITPR2 | Q14571 | 4/20 | 0.35 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.32 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.30 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28927456 | 0.98 | ITPR3 (0.38) | ITPR3BTN3A1ITPR2ITPR1FDPS | |
| SCHEMBL136588 | 0.96 | ITPR3 (0.37) | ITPR3BTN3A1ITPR2ITPR1FDPS | |
| SCHEMBL406797 | 0.96 | ITPR3 (0.37) | ITPR3BTN3A1ITPR2ITPR1FDPS | |
| SCHEMBL134178 | 0.96 | ITPR3 (0.37) | ITPR3BTN3A1ITPR2ITPR1FDPS | |
| SCHEMBL12475062 | 0.96 | ITPR3 (0.37) | ITPR3BTN3A1ITPR2ITPR1FDPS | |
| SCHEMBL544344 | 0.96 | ITPR3 (0.37) | ITPR3BTN3A1ITPR2ITPR1FDPS | |
| SCHEMBL23211993 | 0.94 | ITPR3 (0.36) | ITPR3BTN3A1ITPR2ITPR1FDPS | |
| SCHEMBL5014239 | 0.94 | ITPR3 (0.36) | ITPR3BTN3A1ITPR2ITPR1FDPS | |
| SCHEMBL1983636 | 0.94 | ITPR3 (0.36) | ITPR3BTN3A1ITPR2ITPR1FDPS | |
| SCHEMBL5014242 | 0.94 | ITPR3 (0.36) | ITPR3BTN3A1ITPR2ITPR1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 858 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20250368948-A1 | PRODUCT, SYSTEM AND METHOD OF CELL CULTIVATION | BTL Healthcare Technologies a,s. | 2025-12-04 | — | — | US | claimed |
| CN-119352003-A | Aluminum pop can cover material passivating agent for water-based paint and preparation method thereof | 广州和力表面处理技术有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119310212-A | Liquid quality method for rapidly detecting phytic acid and degradation products thereof in underground water | 中国矿业大学 | 2025-01-14 | — | — | CN | claimed |
| EP-3699271-B1 | GRANULE AND PELLET COMPOSITIONS COMPRISING PHYTASE AND PHYTIC ACID AND PREPARATION METHOD | DANISCO US INC (US) | 2024-09-25 | — | — | EP | claimed |
| CN-112135791-B | Organically modified mineral particles, method for the production and use thereof | 禾大国际股份公开有限公司 | 2024-01-26 | — | — | CN | claimed |
| EP-3974454-B1 | METHOD FOR PREPARING HIGH-PURITY SUGAMMADEX SODIUM | HEFEI BOSIKC PHARMTECH CO LTD (CN) | 2024-01-10 | — | — | EP | claimed |
| WO-2024006972-A1 | THERAPEUTIC TARGETING OF INOSITOL PYROPHOSPHATE SYNTHESIS IN CANCER | THE BROAD INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023180457-A1 | SYNTHETIC GLYCEROPHOSPHOLIPIDS COMPRISING AT LEAST ONE REACTIVE FUNCTION, PROCESS FOR PREPARING SAME AND USES THEREOF IN DIFFERENT APPLICATIONS | UNIVERSITE DE ROUEN-NORMANDIE (FR) | 2023-09-28 | — | — | WO | claimed |
| US-20050272642-A1 | Protecting a muscarinic acetylcholine receptor in Alzheimer patients from oxidative stress, detoxification from toxic metal, by administering at least one pyrophosphates; prevent tissue damage, increasing the efficacy of a therapeutic agent | HEALTHPARTNERS RESEACH FOUNDATION | 2005-12-08 | — | — | US | claimed |
| EP-1278525-A2 | METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR FUNCTION THROUGH PROTECTION OF TISSUE COMPONENTS | Healthpartners Research Foundation (US) | 2003-01-29 | — | — | EP | claimed |
| EP-0649600-B1 | PROCESS FOR PREPARING A GRAIN PRODUCT | NICHIMO COMPANY LTD (JP) | 2002-10-23 | — | — | EP | claimed |
| US-20020028786-A1 | Prevent tissue damage | HEALTHPARTNERS RESEARCH FOUNDATION | 2002-03-07 | — | — | US | claimed |
| WO-2001082932-A2 | METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR FUNCTION THROUGH PROTECTION OF TISSUE COMPONENTS | HEALTHPARTNERS RESEARCH FOUNDATION (US) | 2001-11-08 | — | — | WO | claimed |
| US-5853779-A | Process for preparing grain product | NICHIMO CO., LTD. (JP) | 1998-12-29 | — | — | US | claimed |
| EP-0649600-A1 | CEREAL PRODUCT, USE THEREOF, AND PROCESS FOR PRODUCING THE SAME | NICHIMO COMPANY LIMITED (JP) | 1995-04-26 | — | — | EP | claimed |
| US-5342832-A | Use of mono and di inositolphosphates for treating inflammation | PERSTORP AB (SE) | 1994-08-30 | — | — | US | claimed |
| US-4652449-A | Encapsulating biological active substances into erythrocytes | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1987-03-24 | — | — | US | claimed |
| EP-0101341-B1 | PROCESS AND DEVICE FOR THE ENCAPSULATION IN ERYTHROCYTES OF AT LEAST ONE BIOLOGICALLY ACTIVE SUBSTANCE, IN PARTICULAR HEMOGLOBIN ALLOSTERIC EFFECTORS, AND ERYTHROCYTES SO OBTAINED | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1986-11-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028786-A1 | Prevent tissue damage | VDR, PLPBP, FABP1 | ITPR3 1917/4885BTN3A1 3957/4885ITPR2 1921/4885 |
| US-20050272642-A1 | Protecting a muscarinic acetylcholine receptor in Alzheimer patients from oxidative stress, detoxification from toxic metal, by administering at least one pyrophosphates; prevent tissue damage, increasing the efficacy of a therapeutic agent | CHRM3, ACHE, CHRM2 | ITPR3 363/4885BTN3A1 2916/4885ITPR2 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.